EPS for Spectrum Pharmaceuticals, Inc. (SPPI) Expected At $-0.31

April 17, 2018 - By Migdalia James

Investors sentiment decreased to 1.63 in Q4 2017. Its down 1.21, from 2.84 in 2017Q3. It is negative, as 26 investors sold Spectrum Pharmaceuticals, Inc. shares while 28 reduced holdings. 27 funds opened positions while 61 raised stakes. 78.22 million shares or 9.25% more from 71.60 million shares in 2017Q3 were reported.
Massachusetts-based State Street Corporation has invested 0.01% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Assetmark Inc accumulated 29 shares. Group One Trading Limited Partnership reported 4,375 shares or 0% of all its holdings. First Personal Fincl Ser invested in 370 shares. Fmr Limited Com stated it has 0.02% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Piermont Management Incorporated has 88,372 shares for 0.55% of their portfolio. Aqr Cap Mngmt Ltd Liability stated it has 384,106 shares. 242,128 are held by Morgan Stanley. Rhumbline Advisers owns 210,642 shares for 0.01% of their portfolio. Consonance Cap Management L P has 7.38M shares for 12.64% of their portfolio. Swiss Bank owns 144,000 shares. Balyasny Asset Management Ltd Liability Com invested 0.03% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). 738,472 were accumulated by Invesco Limited. 4.57 million were accumulated by Primecap Management Company Ca. Moreover, Texas Permanent School Fund has 0.01% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI).

Since March 21, 2018, it had 0 insider buys, and 13 insider sales for $6.83 million activity. Riga Thomas J had sold 220 shares worth $3,830. 3,100 shares were sold by Turgeon Joseph W., worth $56,327 on Thursday, March 22. SHROTRIYA RAJESH C MD also sold $953,700 worth of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) shares. GUSTAFSON KURT A had sold 4,350 shares worth $71,123.

Analysts expect Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) to report $-0.31 EPS on May, 1.They anticipate $0.13 EPS change or 72.22 % from last quarter’s $-0.18 EPS. After having $-0.29 EPS previously, Spectrum Pharmaceuticals, Inc.’s analysts see 6.90 % EPS growth. The stock decreased 3.43% or $0.66 during the last trading session, reaching $18.56. About 1.02 million shares traded. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has risen 143.80% since April 17, 2017 and is uptrending. It has outperformed by 132.25% the S&P500.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Ratings Coverage

Among 3 analysts covering Spectrum Pharmaceuticals (NASDAQ:SPPI), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Spectrum Pharmaceuticals had 4 analyst reports since October 24, 2017 according to SRatingsIntel. On Tuesday, April 10 the stock rating was maintained by FBR Capital with “Buy”.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company has market cap of $1.89 billion. The firm markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It currently has negative earnings. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.